Current surgical management of pancreatic endocrine tumor liver metastases

Hepatobiliary and Pancreatic Diseases International

Volumn 10, Issue 3, 2011, Pages 243-247

  Pavlidis, Theodoros E ^a   Psarras, Kyriakos ^b   Symeonidis, Nikolaos G ^b   Pavlidis, Efstathios T ^b   Sakantamis, Athanasios K ^b  

^a Aristotle University of Thessaloniki ^*  (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Debulking surgery; Liver metastases; Neuroendocrine tumors; Pancreas islet cell neoplasms; Pancreatic endocrine tumors; Surgical management

Indexed keywords

ALCOHOL;

ARTIFICIAL EMBOLISM; CHEMOEMBOLIZATION; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MEDLINE; PANCREAS ISLET CELL TUMOR; RADICAL RESECTION; RADIOFREQUENCY ABLATION; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 79959294754     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(11)60040-4     Document Type: Review

References (47)

1. Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS. Clinical experience in diagnosis and treatment of glucagonoma syndrome. Hepatobiliary Pancreat Dis Int 2004;3:473-475.
2. Ekeblad S. Islet cell tumours. Adv Exp Med Biol 2010;654:771-789.
3. Sakurai A, Katai M, Yamashita K, Mori J, Fukushima Y, Hashizume K. Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J 2007;54:295-302.
4. Moayedoddin B, Booya F, Wermers RA, Lloyd RV, Rubin J, Thompson GB, et al. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr Pract 2006;12: 394-400.
5. Falconi M, Bettini R, Boninsegna L, Crippa S, Butturini G, Pederzoli P. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP 2006;7:150-156.
6. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011;30:3-7.
7. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37: 594-618.
8. House MG, Schulick RD. Endocrine tumors of the pancreas. Curr Opin Oncol 2006;18:23-29.
9. Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am 2009;89:1105-1121.
10. Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010;105:1421-1429.
11. Casadei R, Ricci C, Pezzilli R, Campana D, Tomassetti P, Calculli L, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 2010;10:33-38.
12. Goh BK, Chow PK, Tan YM, Cheow PC, Chung YF, Soo KC, et al. Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg 2011;81:79-85.
13. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092.
14. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16:1806-1810.
15. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010;34:723-729.
16. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-255.
17. Zhang L, Lohse CM, Dao LN, Smyrk TC. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol 2011;42:324-331.
18. Chetty R, Serra S, Asa SL. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 2008;32:413-419.
19. Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir (Paris) 2005;142:208-219.
20. Peplinski GR, Norton JA. Gastrointestinal endocrine cancers and nodal metastasis: biologic signifcance and therapeutic implications. Surg Oncol Clin N Am 1996;5:159-171.
21. Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001;81:511-525.
22. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62:51-58.
23. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000;12:368-377.
24. Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998;22:309-318.
25. Tucker ON, Crotty PL, Conlon KC. The management of de Herder WW, Krenning EP, Van Eijck CH, Lamberts SW Considerations concerning a tailored, individualized therapeutic management of patients with (neuro) endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004;11:19-34.
26. Modlin IM, Lewis JJ, Ahlman H, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993;176:507-518.
27. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg 2011;396:299-311.
28. Máthé Z, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011;91:575-582.
29. Chung JC, Choi DW, Jo SH, Heo JS, Choi SH, Kim YI. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 2007;31:579-585.
30. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2008;12:382-393.
31. Schneider R, Waldmann J, Swaid Z, Ramaswamy A, Fendrich V, Bartsch DK, et al. Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity. Pancreas 2011;40:213-221.
32. Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008;32:904-917.
33. Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol 2011;103:169-174.
34. Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007;188:1201-1207.
35. de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008;19:855-861.
36. Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1998;14:175-183.
37. Okada T, Nishimura T, Nakamura M, Sakata K, Katou A, Setoguchi M, et al. Non-functional pancreatic endocrine carcinoma with multiple liver metastases--a case report. Gan To Kagaku Ryoho 2010;37:2370-2372.
38. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010;148:1288-1293.
39. Pfeifer AK, Gregersen T, Grenbask H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide Receptor Radionuclide Therapy with Y-DOTATOC and (177)Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland. Neuroendocrinology 2011;93: 189-196.
40. Nisa L, Savelli G, Giubbini R. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review. Ann Nucl Med 2011;25:75-85.
41. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
42. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
43. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by geftinib (ZD1839). Br J Cancer 2003;89:1766-1775.
44. Biliotti G, Martini F, Vaggelli L, Messerini L, Colagrande S, Pupi A, et al. Multiple effects of somatostatin analogs verifed in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system. Tumori 2006;92:170-174.
45. Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin North Am 2010;39:811-826.
46. Zarebczan B, Chen H. Signaling mechanisms in neuroendocrine tumors as targets for therapy. Endocrinol Metab Clin North Am 2010;39:801-810.
47. Teh SH, Deveney C, Sheppard BC. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifable? Am J Surg 2007;193:610-613.